From the Journals

Virtual yoga program appears to improve IBS symptoms, fatigue, stress


 

FROM THE AMERICAN JOURNAL OF GASTROENTEROLOGY

Future program considerations

Dr. Raman and colleagues are interested in understanding the mechanisms that underlie the efficacy of mind-body interventions. They also plan to test the virtual yoga program in a mobile app, called LyfeMD, which is intended to support patients with digestive diseases through evidence-based dietary programs and mind-body interventions, such as guided meditation, breathing exercises, and cognitive behavioral therapy.

“We know that patients are looking for all possible resources,” Dr. Raman said. “Our next goal is to better understand how an app-based intervention can be effective, even without a live instructor.”

Future studies should also consider clinicians’ perspectives, she noted. In previous studies, Dr. Raman and colleagues have found that physicians are open to recommending yoga as a therapeutic option for patients, but some are unsure how to prescribe a recommended dose, frequency, or type of yoga.

“When treating patients with IBS, it is important to think broadly and creatively about all our treatment options,” said Elyse Thakur, PhD, a clinical health psychologist at Atrium Health Gastroenterology and Hepatology, Charlotte, N.C.

Dr. Thakur, who wasn’t involved with this study, specializes in gastrointestinal health psychology. She and colleagues use numerous complementary and alternative medicine options with patients.

“We have to remember that people may respond differently to available treatment options,” she said. “It is imperative to understand the evidence so we can have productive conversations with our patients about the pros and cons and the potential benefits and limitations.”

The study did not receive a specific grant from a funding agency. The authors and Dr. Thakur declared no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

‘Unappreciated’ ties between COVID and gut dysbiosis
Federal Practitioner
FDA rejects bulevirtide for hepatitis D
Federal Practitioner
Patients at risk for Barrett’s esophagus rarely screened
Federal Practitioner
Noninvasive tests may provide prognostic value in NAFLD
Federal Practitioner
Liver disease-related deaths rise during pandemic
Federal Practitioner
Doctors urge screening for autoimmune disorders for patients with celiac disease
Federal Practitioner
Poor NAFLD outcomes with increased VCTE-measured liver stiffness
Federal Practitioner
Could intermittent fasting improve GERD symptoms?
Federal Practitioner
Study supports banning probiotics from the ICU
Federal Practitioner
FDA OKs first fecal transplant therapy for recurrent C. difficile
Federal Practitioner